LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Aandelen Lijst・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

628.61 1.61

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

618.69

Max

631.75

Belangrijke statistieken
By Trading Economics
Inkomsten	-117M 727M
Verkoop	-279M 3.6B
K/W Sectorgemiddelde	14.661 49.888
EPS	9.47
Dividendrendement	0.58
Winstmarge	20.17
Werknemers	15,343
EBITDA	-234M 967M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+34.06% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	0.58% 2.38%
Volgende Winsten	31 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-15B 63B
Vorige openingsprijs	627
Vorige sluitingsprijs	628.61

Nieuwssentiment

By Acuity

41%

59%

132 / 344 Rangschikking in Healthcare

Regeneron Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 aug 2025, 11:33 UTC

Winsten

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

29 apr 2026, 12:01 UTC

Winsten

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

23 apr 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

11 mrt 2026, 11:02 UTC

Marktinformatie

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

14 dec 2025, 08:30 UTC

Acquisities, Fusies, Overnames

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

1 aug 2025, 13:16 UTC

Winsten

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 aug 2025, 12:40 UTC

Winsten

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 aug 2025, 10:41 UTC

Winsten

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1 aug 2025, 10:41 UTC

Winsten

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1 aug 2025, 10:40 UTC

Winsten

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1 aug 2025, 10:38 UTC

Winsten

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1 aug 2025, 10:37 UTC

Winsten

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1 aug 2025, 10:35 UTC

Winsten

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1 aug 2025, 10:34 UTC

Winsten

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1 aug 2025, 10:33 UTC

Winsten

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1 aug 2025, 10:32 UTC

Winsten

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1 aug 2025, 10:31 UTC

Winsten

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1 aug 2025, 10:31 UTC

Winsten

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1 aug 2025, 10:30 UTC

Winsten

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1 aug 2025, 10:30 UTC

Winsten

Regeneron Pharma 2Q Rev $3.68B >REGN

1 aug 2025, 10:30 UTC

Winsten

Regeneron Pharma 2Q EPS $12.81 >REGN

1 aug 2025, 10:30 UTC

Winsten

Regeneron Pharma 2Q Net $1.39B >REGN

13 jun 2025, 21:42 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 jun 2025, 20:45 UTC

Acquisities, Fusies, Overnames

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 jun 2025, 20:34 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

Peer Vergelijking

Prijswijziging

Regeneron Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

34.06% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 829.77 USD 34.06%

Hoogste 995 USD

Laagste 641 USD

Gebaseerd op 22 Wall Street-analisten die 12-maands prijsdoelen bieden voor Regeneron Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

22 ratings

Buy

Hold

Sell

Gebaseerd op 22 analisten die aandelenratings hebben gegeven aan Regeneron Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

132 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.